Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Q3 2025 Earnings Presentation
23 slides from Oncoinvent Asa's earnings presentation, Nov 4, 2025
Slide 1: Third quarter 2025 update
Oncoinvent Third quarter 2025 update Transforming cancer care through direct alpha therapy 1
Slide 2: Disclaimer and important information
Disclaimer and important information This presentation, together with its enclosures and appendices (collectively, the “Presentation”), has been prepared by Oncoinvent ASA solely for the purpose of providing existing investors and other stakeholders in the Companies with an update on the company as
Slide 3: Highlights, Upcoming Milestones, Clinical Update
Highlights Upcoming Milestones Clinical Update
Slide 4: Recent Highlights
Recent Highlights Ovarian cancer: Reported final results and promising signal of efficacy from phase 1 trial Radspherin® Colorectal cancer: Presented final results from the Phase 1/2a trial at the 15th PSOGI International Congress on Peritoneal Surface Malignancies Completed merger with BerGenBio Co
Slide 5: Highlights, Upcoming Milestones, Clinical Update
Highlights Upcoming Milestones Clinical Update
Slide 6: Merger successfully completed, rights issue to be launched 17 November
Merger successfully completed, rights issue to be launched 17 November Details of the merger and the rights issue Merger successfully completed Fully underwritten rights issue of NOK 130 mill. ✓ Merger with BerGenBio successfully completed 29 October 2025. 11 • Price date – based on Volume Weighted
Slide 7: Cash and runway
Cash and runway Cash Oncoinvent per end 3Q As of the 30. September 2025 Oncoinvent had a total of NOK 45 mill. in cash and cash equivalents As at the date of the Prospectus, the Company holds Estimated cash from approximately NOK 45 mill. in cash and cash equivalents BerGenBio and rights issue Fully
Slide 8: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 8
Slide 9: Highlights, Upcoming Milestones, Clinical update
Highlights Upcoming Milestones Clinical update
Slide 10: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 10
Slide 11: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 11
Slide 12: Radspherin® - phase 1 study in ovarian cancer
Radspherin® - phase 1 study in ovarian cancer RAD-18-001: in patients after secondary debulking 4 clinical sites: surgery of platinum-sensitive recurrent ovarian cancer • Oslo, Norway (PI: Yun Wang) • single-arm open label study • Leuven, Belgium (PI: Els van Nieuwenhuysen) • 3 + 3 dose-escalation (
Slide 13: Radspherin® - phase 1 study in ovarian cancer - safety
Radspherin® - phase 1 study in ovarian cancer - safety Dose 1MBq Dose 2 MBq Dose 4 MBq Dose 7 MBq Total (n=3) (n=3) (n=4) (n=11) (n=21) Number of 18 22 24 42 106 • The most frequently reported adverse adverse events events were nausea, abdominal pain, constipation, vomiting, urinary tract Patients w
Slide 14: Radspherin® - phase 1 study in ovarian cancer - efficacy
Radspherin® - phase 1 study in ovarian cancer - efficacy 24 months data from 10 patients receiving 7 MBq dose vs historical recurrence rates Recurrence rates RAD-18-001 “These final results are truly encouraging, suggesting that Radspherin® could help delay 10 % disease progression and offer 30 % pa
Slide 15: Radspherin® - phase 1 study in ovarian cancer - efficacy
Radspherin® - phase 1 study in ovarian cancer - efficacy 24 months data from 10 patients receiving 7 MBq dose vs historical recurrence rates Recurrence rates RAD-18-001 Recurrence rates historical controls “These final results are truly encouraging, suggesting that Radspherin® could help delay 10 %
Slide 16: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 16
Slide 17: Phase 2 study in ovarian cancer – frontline treatment setting
Phase 2 study in ovarian cancer – frontline treatment setting Patients • with peritoneal metastases SoC+ Radspherin Assessment Randomised Primary (60 patients) every 3 months • after neoadjuvant Safety run-in cohort endpoint: (6 patients) 2:1 up to 24 chemotherapy (90 patients) months, progression-f
Slide 18: Patient recruitment update end Q3
Patient recruitment update end Q3 All six hospitals are actively recruiting patients and patient recruitment is on track Number of hospitals will increase in November and December, which will Recruitment in July and August was seasonally speed up recruitment rate limited. Selected changes to protoco
Slide 19: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results 19
Slide 20: Presentation of Phase 1/2a study results in colorectal cancer
Presentation of Phase 1/2a study results in colorectal cancer Peritoneal recurrence rate in 36 patients receiving 7 MBq dose vs historical control Radspherin® Historical control 28% 50 % 28% ~50% Peritoneal recurrence rate Peritoneal recurrence rate Quenet et al. Lancet Oncol. 2021 Feb;22(2):256-266
Slide 21: Near-term significant milestone
Near-term significant milestone Interim data Phase 2 Following complete recruitment ovarian cancer 2H26 Final 24 months data Phase 1 10 patients 7 MBq ovarian cancer October 2025 Final 18 months data Phase 1/2a colorectal cancer 36 patients 7 MBq June 2025 21
Slide 22: Financial Calendar
Financial Calendar today Quarterly update Q3-25 26 February Half-year report H2-25 30 April Quarterly update Q1-26 20 May Annual General Meeting 27 August Half-year report H1-26 28 October Company update Q3-26 22
Slide 23: Questions
Questions OnNCO invent